New cancer drug to begin trials in multiple myeloma patients

13 octubre 2014

A new cancer drug has been developed, which researchers plan to trial in multiple myeloma patients by the end of next year. The researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs. The new drug works by stopping a key process that allows cancer cells to multiply.